INDOMETHACIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Indomethacin, and when can generic versions of Indomethacin launch?
Indomethacin is a drug marketed by Able, Amneal Pharms, Aurobindo Pharma, Avanthi Inc, Chartwell Rx, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Inwood Labs, Jubilant Generics, Mylan, Novast Labs, Sandoz, Watson Labs Inc, Zydus Pharms, Ani Pharms, Chartwell Molecules, Cycle, Duramed Pharms Barr, Halsey, Heritage, Heritage Pharma, Ivax Sub Teva Pharms, Mutual Pharm, Parke Davis, Pioneer Pharms, Rising, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Teva, Watson Labs, Zydus Lifesciences, Fresenius Kabi Usa, Cosette, Hikma, Novitium Pharma, Hospira, Navinta Llc, and West-ward Pharms Int. and is included in sixty-four NDAs.
The generic ingredient in INDOMETHACIN is indomethacin sodium. There are fifteen drug master file entries for this compound. Additional details are available on the indomethacin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Indomethacin
A generic version of INDOMETHACIN was approved as indomethacin sodium by WEST-WARD PHARMS INT on July 16th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INDOMETHACIN?
- What are the global sales for INDOMETHACIN?
- What is Average Wholesale Price for INDOMETHACIN?
Summary for INDOMETHACIN
| US Patents: | 0 |
| Applicants: | 39 |
| NDAs: | 64 |
| Finished Product Suppliers / Packagers: | 32 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 178 |
| Drug Prices: | Drug price information for INDOMETHACIN |
| Drug Sales Revenues: | Drug sales revenues for INDOMETHACIN |
| What excipients (inactive ingredients) are in INDOMETHACIN? | INDOMETHACIN excipients list |
| DailyMed Link: | INDOMETHACIN at DailyMed |
See drug prices for INDOMETHACIN
Recent Clinical Trials for INDOMETHACIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Mostar | Phase 2/Phase 3 |
| GlaxoSmithKline | Phase 1 |
| Moti Lal Nehru Medical College | N/A |
Pharmacology for INDOMETHACIN
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Medical Subject Heading (MeSH) Categories for INDOMETHACIN
US Patents and Regulatory Information for INDOMETHACIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences | INDOMETHACIN | indomethacin | SUPPOSITORY;RECTAL | 216184-001 | Aug 2, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mutual Pharm | INDOMETHACIN | indomethacin | CAPSULE;ORAL | 070068-001 | Oct 3, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Heritage Pharma | INDOMETHACIN | indomethacin | CAPSULE;ORAL | 070719-001 | Feb 12, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | INDOMETHACIN | indomethacin | CAPSULE;ORAL | 070673-001 | Apr 29, 1987 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
